Waikoloa, Hawaii - Psoriatic patients responding to efalizumab (Raptiva, Genentech Inc. and Xoma Ltd.) biologic medication are happy with the results after an extended period of continuous treatment.
The Weekly Roundup: January 16-20
The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice
Drug Price Hikes Already Found in 2023
The Cutaneous Connection: An Inside Look of the Inclusive Atlas
Positive Topline Results Announced for Oral Orismilast for Treatment of Psoriasis
The Weekly Roundup: January 2-6